Michael Feld, MD

Behind every extended-release stimulant is an engineering problem: how to release medication predictably over hours. The panel breaks down the microparticle and polymer technologies making that possible.

Sensory sensitivity, weekend flexibility, and hyperfocus all shape how adults actually take their ADHD medication. The panel explains why formulation choice can matter as much as the molecule.

Non-stimulants play a growing, specific role in adult ADHD care, from tolerability limits to emotional regulation. The panel details exactly when to add one to a treatment plan.

Immediate-release booster doses ask patients with executive dysfunction to remember, calculate, and decide, often at the worst possible moment. The panel explains why this adherence trap undermines treatment.

A regimen that has worked for twenty years may still be leaving symptoms untreated. The panel makes the case for revisiting long-standing ADHD prescriptions in light of newer technology.

Treating ADHD only during visible hours leaves patients unprotected at the moments that matter most. The panel argues for symptom control that extends through bedtime, not just the workday.

Extended-release stimulants have become first-line therapy for adult ADHD, replacing outdated practices that once set patients up for failed medication trials. The panel explains why.

ADHD rarely confines itself to one area of an adult's life. The panel traces how the condition's burden compounds across work, family, and relationships as responsibilities grow.

Untreated ADHD carries measurable costs in relationships, careers, and even life expectancy. The panel makes the clinical case for diagnosing and treating adult ADHD as early as possible.

Many adults with ADHD are hiding in plain sight behind a prior anxiety or depression diagnosis. The panel examines underdiagnosis trends and how to identify ADHD beneath common comorbid conditions.

Diagnosing adult ADHD demands more than a single office visit. The panel outlines the history-taking, collateral information, and follow-up structure needed to reach a confident, accurate diagnosis.

Adult ADHD is more common than clinicians assume, and its symptoms look different from the classic childhood presentation. The panel opens by reframing prevalence and heterogeneity as the foundation for accurate diagnosis.